Compare HRB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | DNTH |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.8B |
| IPO Year | 1994 | 2018 |
| Metric | HRB | DNTH |
|---|---|---|
| Price | $29.82 | $87.17 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $41.00 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.6M | 753.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 4.39 | N/A |
| Revenue | ★ $3,159,931,000.00 | $2,036,000.00 |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.21 | $29.48 |
| P/E Ratio | $7.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.16 | $16.77 |
| 52 Week High | $64.62 | $96.50 |
| Indicator | HRB | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 54.75 |
| Support Level | $29.75 | $33.94 |
| Resistance Level | $32.70 | $88.45 |
| Average True Range (ATR) | 1.20 | 3.74 |
| MACD | -0.05 | -1.19 |
| Stochastic Oscillator | 6.68 | 33.16 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.